Artículos (Farmacología)
URI permanente para esta colecciónhttps://hdl.handle.net/11441/11025
Examinar
Envíos recientes
Artículo Dietary freeze-dried beer prevents inflammation in DSS-induced chronic ulcerative colitis in mice(Royal Society of Chemistry, 2025-07-01) Paredes Sánchez, María; Muñoz García, Rocío; Ávila Román, Francisco Javier; Lobo Prieto, Ana; Orta Cuevas, María del Mar; García González, Diego L.; Vázquez Román, María Victoria; Talero Barrientos, Elena Mª; Sánchez Hidalgo, Marina; Farmacología; Química Analítica; Citología e Histología Normal y PatológicaInflammatory bowel disease (IBD) is a complex condition that is influenced by numerous factors, including genetic, immune and environmental factors. In the search for new therapies, nutritional interventions including dietary polyphenols are becoming increasingly important in the management of IBD. The present study aimed to investigate the antioxidant and anti-inflammatory effects of commercial freeze-dried beer, an interesting product resulting from the fermentation of cereals, rich in polyphenols, in (I) an in vitro model of inflammation using lipopolysaccharide (LPS)-stimulated THP-1 human derived macrophages and (II) a murine dextran sodium sulfate (DSS)-induced chronic colitis model, for elucidating the action mechanism involved. According to the results, commercial freeze-dried beer exhibits antioxidant, anti-inflammatory and immunomodulatory properties in LPS-stimulated THP-1 human macrophages by reducing reactive oxygen species (ROS), tumor necrosis factor (TNF)-α and interleukin (IL)-6 levels. Moreover, in vivo results showed that preventive treatment with dietary freeze-dried beer improved murine DSS-induced chronic colitis by attenuation of the clinical and histological signs of colonic damage. Colonic cytokine levels in animals fed with commercial freeze-dried beer reached values near basal levels. In addition, pro-inflammatory cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 protein expressions were significantly downregulated via inhibition of nuclear transcription factor kappa B (NF-κB) translocation. This inhibition may be mediated by an induction of the antioxidant nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway and a reduction of signal transducer and activator of transcription (STAT)-3 phosphorylation orchestrating its potent anti-inflammatory and immunomodulatory effects. Overall, our results suggest that dealcoholized beer may be effective in the management of immune-mediated inflammatory diseases in which macrophages are crucial, including IBD, providing clues for developing useful dietary interventions against inflammation-associated pathologies.Artículo Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project(Elsevier, 2025-05) Moreno Mellado, Elisa; Aslan, Abdullah Tarik; Akova, Murat; León, Eva; Merchante Gutiérrez, Nicolás; Vinuesa, David; Merino Bohórquez, Vicente; Rodríguez-Baño, Jesús; Docobo Pérez, Fernando; Gutiérrez Gutiérrez, Belén; Universidad de Sevilla. departamento de Medicina; Universidad de Sevilla. departamento de Farmacología; Universidad de Sevilla. departamento de Microbiología; CIBERINFEC; European Union (UE); Gobierno de España; Instituto de Salud Carlos IIIObjectives: The FOSFOMIC study assessed the clinical and microbiological effectiveness, and safety of intravenous fosfomycin in treating complicated urinary tract infections (cUTIs) caused by Escherichia coli, in comparison with other intravenous antimicrobials. Methods: A prospective, multinational matched cohorts study involving adults with community-acquired cUTIs and receiving targeted therapy with intravenous fosfomycin or other first-line drugs (beta-lactams or fluoroquinolones) was conducted from November 2019 to May 2023 in ten centres from Spain, Italy, and Türkiye. Matching criteria included type of infection acquisition, Charlson and Pitt scores. Endpoints were clinical and microbiological cure, mortality, recurrence, and adverse effects. Analyses used conditional logistic regression and desirability of outcome ranking (DOOR). Results: Overall, 155 matched pairs were included. Clinical and microbiological cure rates were 65.2% (101/155; 95% CI, 57.4–72.2) and 63.2% (98/155; 95% CI, 55.4–70.4) with fosfomycin and comparators, respectively (adjusted OR, 1.09; 95% CI, 0.68–1.73; p 0.73). Mortality rates were 1.9% (3/155; 95% CI, 0.7–5.5) and 5.8% (9/155; 95% CI, 3.1–10.7), respectively (p 0.11). Recurrence rates were 14.2% (22/155; 95% CI, 9.6–20.6) in the fosfomycin group vs. 10.3% (16/155; 95% CI, 6.1–16.1) (p 0.39). Severe adverse effects occurred in 1.9% (3/155; 95% CI, 0.7–5.5) of patients treated with fosfomycin vs. 0.6% (1/155; 95% CI, 0.0–3.3) in the control group (p 0.62). Non-severe adverse effects were more frequent with fosfomycin, affecting 23.3% (36/155; 95% CI, 17.0–30.7) compared with 7.7% (12/155; 95% CI, 4.1–13.1) in the control group (adjusted OR, 5.36; 95% CI, 2.04–14.1; p < 0.001). In DOOR analysis, fosfomycin demonstrated comparable effectiveness in treating pyelonephritis (probability of better DOOR, 54.0%; 95% CI, 48.5–59.6) and in comparison with ceftriaxone (50.3%; 95% CI, 44.7–55.8), without evidence of inferiority in bacteraemic urinary tract infections (DOOR, 47.3%; 95% CI, 41.7–52.8). Discussion: Fosfomycin is a viable option for treating cUTIs caused by E. coli, allowing for diversification in the treatment of these high-incidence infections.Artículo Exploring the Broad-spectrum Activity of Carbohydrate-based Iberin Analogues: From Anticancer Effect to Antioxidant Properties(Elsevier, 2025) Prieto Ramírez, Luis Alberto; Khiar Fernández, N.; Calderón Montaño, José Manuel; López Lázaro, Miguel; Lucía Tamudo, J.; Nogueira, J. J.; León, R.; Moreno Rodríguez, Nazaret; Valdivia Giménez, Victoria Esther; Recio Jiménez, Rocío; Fernández Fernández, Inmaculada; Química Orgánica y Farmacéutica; Farmacología; Ministerio de Ciencia e Innovación (MICIN). España; Universidad de SevillaIberin is a lower homologue of sulforaphane (SFN) which has shown effectiveness in addressing various pathologies, including its anti-inflammatory properties, antitumor activity against various cancers, and antimicrobial effects. Building on this activity, a series of carbohydrate-based analogues of the natural isothiocyanate (ITC) iberin were synthesized, and their anticancer and antioxidant activities were evaluated. Cytotoxicity studies on three cancer cell lines using Resazurin assay demonstrated significant cytotoxic activity, particularly against bladder cancer. The sulfonyl derivatives exhibited the most potent effects, with IC50 values comparable to those of reference natural isothiocyanates (from 10 to 20 μM). Computational simulations support the hypothesis that carbohydrate-based ITCs can interact with STAT3's SH2 domain in a manner similar to SFN, laying the groundwork for their potential development as STAT3-targeted anticancer agents. The antioxidant potential of these compounds was assessed by their ability to activate the Nrf2 factor, yielding CD values (concentration required to double luciferase activity compared to basal conditions) between 1.55 and 10.36 μM, without cytotoxicity at these concentrations. Notably, the phenylsulfone derivative 22β displayed slightly higher or comparable antioxidant activity to that of natural isothiocyanates. Based on these findings, this phenylsulfone analogue was selected as the optimal compound due to its dual anticancer and antioxidant activities. An additional advantage of this carbohydrate-based ITC is that it is a solid compound, making it easier to handle than natural isothiocyanates, which are typically liquids.Artículo Estudio cualitativo sobre la adopción y puesta en valor del modelo capacidad-motivación-oportunidad de atención farmacéutica en las consultas externas de farmacia en España(Elsevier, 2025-04-01) Álvarez Díaz, Ana María; Crespo Diz, Carlos; Monte Boquet, Emilio; Marcos Rodríguez, José Antonio; Margusino Framinan, Luis; Sánchez Yañez, Elena; Morillo Verdugo, Ramón Alejandro; Universidad de Sevilla. Departamento de FarmacologíaObjetivo analizar y abordar las barreras que los servicios de farmacia se encuentran en el momento de la adopción del modelo de atención farmacéutica capacidad-motivación-oportunidad (CMO) en consultas externas, identificando los actores relevantes en el ecosistema, así como las motivaciones. Por último, realizar un primer acercamiento a soluciones que nos ayuden a seleccionar las que podrían llevarse a desarrollo a través de iniciativas futuras. Método se desarrolló una metodología estructurada en varias fases, incluyendo la formación de 2 equipos de trabajo: el «Equipo Rector», compuesto por farmacéuticos hospitalarios con experiencia en atención farmacéutica y humanización asistencial, y el «Equipo Core», integrado por profesionales de diversas disciplinas. La primera fase consistió en la realización de un taller de prospección online para explorar las fases de adopción del modelo. Posteriormente, se realizaron entrevistas semiestructuradas a actores clave (médicos, gerentes y asociaciones de pacientes) para identificar necesidades y barreras. Finalmente, se realizó un taller presencial que facilitó la ideación de soluciones y validación de propuestas. Resultados se identificaron 3 categorías de actores en el ecosistema del modelo CMO: agentes interesados (beneficiarios), agentes interesantes (influenciadores) y agentes ejecutivos (implementadores). Se evidenciaron diversas barreras, como la variabilidad en la infraestructura, la falta de interés de los gestores y la sobrecarga laboral de los farmacéuticos. No obstante, se observó una creciente motivación por parte de los profesionales y organizaciones para adoptar el modelo. Durante el taller de ideación se priorizaron 10 iniciativas, que incluyeron el uso de tecnologías digitales y programas de formación continua. Conclusión se destaca el alto potencial del modelo CMO para mejorar la atención farmacéutica en consultas externas de farmacia hospitalaria en España, a pesar de las barreras existentes. Las estrategias propuestas, centradas en la digitalización y la colaboración multidisciplinar, son clave para su implementación efectiva. Se sugiere la necesidad de futuras investigaciones para evaluar el impacto a largo plazo de estas iniciativas y fortalecer la implicación de asociaciones de pacientes y otros actores en el proceso de adopción.Artículo Influence of antiretroviral therapy on frailty among people living with HIV(Nature Research, 2025-04-25) Contreras Macías, Enrique; Robustillo Cortés, María de las Aguas; Morillo Verdugo, Ramón Alejandro; Universidad de Sevilla. Departamento de FarmacologíaThe aim of this study is to determine the influence of ARV on the diagnosis of frailty in PLWH. A single-centre prospective observational study was conducted involving PLWH over 18 years old who attended a hospital pharmacy outpatient service between January 2010 and December 2021. Participants were assessed for frailty using the Fried Frailty Phenotype scale and for geriatric syndromes including falls, cognitive impairment, depression, polypharmacy, and risk of malnutrition. ARV regimens were categorized by drug classes and the number of drugs. Associations between ARV and frailty were evaluated using multivariate logistic regression model. 729 PLWH were included, median age of 52 years. Frailty was observed in 15.6% of the participants, with an additional 48.4% classified as pre-frail. Comorbidities were present in 51.7%, with cardiovascular diseases being the most common. Geriatric syndromes were prevalent in 17.1% of the participants, with polypharmacy noted in 15.2%. the study concludes that while specific ARV regimens do not directly influence frailty development in PLWH, prolonged ARV exposure and polypharmacy significantly increase frailty risk. These findings highlight the need for comprehensive management strategies that optimize ARV regimens and minimize polypharmacy to improve the prognosis and quality of life for aging PLWH.Artículo Impact of training healthcare professionals in the detection and management of neuropsychiatric comorbidities in people with HIV: The CONECTAR project in Spain(Wiley, 2025-02-24) Blanch, Jordi; Martínez, Esteban; Mena, Álvaro; Dueñas, Carlos; Bernal, Enrique; Cabello, Alfonso; Morillo Verdugo, Ramón Alejandro; Pérez Valero, Ignacio; Universidad de Sevilla. Departamento de FarmacologíaIntroduction Although anxiety, depression and insomnia in people with HIV (PWH) are prevalent and have a major impact on clinical outcomes and quality of life, physicians fail to evaluate them routinely. The CONECTAR Project [Neuropsychiatric Comorbidity (NPC): Key to Antiretroviral Treatment] aimed to improve NPC clinical care in PWH in Spain by upskilling healthcare professionals (HCPs). Methods A group of HCPs developed a training programme, supported by national and international guidelines, to improve expertise on detecting and managing NPCs in PWH. The programme was conducted through workshops for physicians and nurses in various Spanish regions from April to November 2023; survey questionnaires were administered to physicians before the commencement of training and 15 days after. Later, a workshop was held for nurses who manage NPCs in PWH. Results The programme was completed by 64 physicians (22 had completed both questionnaires) and 11 nurses (no feedback obtained). Feedback from physicians reflected that the programme boosted awareness and self-perception of being more qualified, knowledgeable and able to use management tools and resources. Physicians also reported improved perception of time available for visits and more frequent enquiries about patients' NPC symptoms. Despite their satisfaction with the workshops, half of the physicians recognized the need for more training. Conclusion The CONECTAR Project was a successful training programme that was well received and valued by HCPs who routinely manage NPCs in PWH. Institutions involved in HCP training to manage anxiety, depression and insomnia more effectively in PWH should consider similar proposals to reinforce clinical practices.Artículo Factors Associated with Adequate Quality of Life Levels in HIV Patients During a Five-Year Longitudinal Study(Sociedad Española de Quimioterapia, 2025-04-16) Contreras Macías, Enrique; Morillo Verdugo, Ramón Alejandro; Universidad de Sevilla. Departamento de FarmacologíaIntroduction: Advances in antiretroviral therapy (ARV) have improved the life expectancy of people living with HIV (PLWH), shifting the focus to quality of life (QoL). However, aging, polypharmacy, and comorbidities pose challenges. This study aimed to evaluate the evolution of QoL over five years and identify associated sociodemographic, clinical, and pharmacotherapeutic factors. Methods: A single-center retrospective observational study was conducted in PLWH attending a tertiary hospital outpatient pharmacy. QoL was assessed using the EQ-5D-5L questionnaire. Sociodemographic, clinical, and pharmacotherapeutic variables—including age, polypharmacy, comorbidities, and Medication Regimen Complexity Index (MRCI)—were analyzed. Multivariate logistic regression identified predictors of good QoL, defined as a Visual Analogue Scale (VAS) score ≥76. Results: A total of 437 PLWH were included with median age 52 years. The participants were majority male (82.8%). Throughout the study, mean VAS scores remained stable, with 63.7–73.4% of participants reporting good QoL each year. The most frequently reported issues were related to mobility (8.9%), pain/discomfort (5.1%), and anxiety/depression (3.0%). Multivariate analysis showed that advanced age (OR: 1.55, 95%CI: 1.14–2.11), polypharmacy (OR: 1.87, 95%CI: 1.35–2.59), comorbidities (OR: 2.13, 95%CI: 1.76–2.89), and socioeconomic problems (OR: 2.47, 95%CI: 1.44–4.21) were significantly associated with lower QoL. Conclusion: Aging, polypharmacy, and socioeconomic disparities significantly impact QoL in PLWH. Integrating QoL assessments into routine care and addressing these factors through comprehensive management strategies could enhance long-term well-being.Artículo Effects of dietary fats (fish, olive and high-oleic-acid sunflower oils) on lipid composition and antioxidant enzymes in rat liver(Cambridge University Press, 1999) Ruiz Gutiérrez, Valentina; Pérez Espinosa, Alonso; Vázquez Cueto, Carmen María; Santa-María Pérez, Consuelo; Universidad de Sevilla. Departamento de Farmacología; Comisión Interministerial de Ciencia y Tecnología (CICYT). EspañaThe effects of two oleic-acid-rich diets (containing olive oil, OO, and high-oleic-acid sunflower oil, HOSO) on plasma and liver lipid composition detoxification enzyme activities, were compared with those of a fish-oil (FO) diet and a control diet. Compared with the control diet, plasma and hepatic total triacylglycerol concentrations were increased in the animals fed on the HOSO and OO diets and decreased in those fed on the FO diet. The animals fed on FO showed the highest level of cholesterol in the liver and had lower plasma cholesterol concentrations when compared with those fed on the two oleic-acid-rich diets. In comparison with the animals fed on the diets enriched in oleic acid, the FO group showed higher hepatic levels of polyunsaturated fatty acids of the n-3 series and lower levels of fatty acids of the n-6 series. Livers of FO-fed rats, compared with those of OO- and HOSO-fed rats showed: (1) significantly higher activities of catalase (EC 1.11.1.6) glutathione peroxidase (EC 1.11.1.9) and Cu/Zn superoxide dismutase (EC 1.15.1.1); (2) no differences in the NADPH-cytochrome c reductase (EC 1.6.99.3) activity. The HOSO diet had a similar effect on liver antioxidant enzyme activities as the OO diet. In conclusion, it appears that changes in the liver fatty acid composition due mainly to n-3 lipids may enhance the efficiency of the antioxidant defence system. The two monounsaturated fatty acids oils studied (OO and HOSO), with the same high content of oleic acid but different contents of natural antioxidants, had similar effects on the antioxidant enzyme activities measured.Artículo Effects of dietary oleic-rich oils (virgin olive and high-oleic-acid sunflower) on vascular reactivity in Wistar-Kyoto and spontaneously hypertensive rats(Cambridge University Press, 2001) Herrera González, María Dolores; Pérez Guerrero, María Concepción; Marhuenda Requena, Elisa; Ruiz Gutiérrez, Valentina; Comisión Interministerial de Ciencia y Tecnología (CICYT). EspañaThe effects of two monounsaturated fatty acid (MUFA)-rich diets, containing virgin olive oil (OO) and high-oleic-acid sunflower oil (HOSO), on development of vascular response from isolated thoracic rat aorta and lipid composition and fatty acid composition were studied and compared with samples from rats fed on a control diet. Dietary MUFA oils were fed for 6 weeks to spontaneously hypertensive (SHR) and Wistar–Kyoto (WKY) rats from 4 weeks of age. The maximum contraction of aortic ring preparations in response to phenylephrine (10-6 M) WAS SIGNIFICANTLY DECREASED IN SHR RATS FED WITH OO (0·81 (sem 0·05) v. 1·18 (sem 0·09) g, P<0·01) and treatment with HOSO did not alter the phenylephrine-induced contractions. The relaxant responses to acetylcholine (10-5 m) were significantly enhanced (30·03 (sem 0·70) v. 18·47 (sem 0·28) %, P<0·001) in the rings from SHR rats treated with OO, and were more pronounced than in WKY rats (P<0·05). In the same way, OO attenuated the dose–response curves induced by phenylephrine (10-8–10-5 m) from SHR rats, accompained with a slower contraction. These results suggest that only the chronic feeding of OO diet was able to attenuate the vascular response of rat aorta. In addition, an increase in phospholipid content (186·7 (sd 3·2) v. 159·1 (sd 11·3) g/kg, P<0·01) and changes in the fatty acid composition of aorta (mainly a decrease in arachidonic acid) could contribute to improving endothelial function. Therefore, the effects can not be attributed exclusively to the content of MUFA (mainly oleic acid). Other components of OO, such as polyphenols, not present in HOSO, may help to explain the vascular protective effect of OO consumption.Artículo Virgin olive oil and its phenol fraction modulate monocyte/macrophage functionality: a potential therapeutic strategy in the treatment of systemic lupus erythematosus(Cambridge University Press, 2018-07-31) Aparicio Soto, Marina; Montserrat de la Paz, Sergio; Sánchez Hidalgo, Marina; Cárdeno Galván, Ana; Bermúdez Pulgarín, Beatriz; García Muriana, Francisco José; Alarcón de la Lastra Romero, Catalina; Universidad de Sevilla. Departamento de Farmacología; Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología; Universidad de Sevilla. Departamento de Biología Celular; Ministerio de Ciencia e Innovación (MICIN). España; Junta de Andalucía; Universidad de SevillaMonocytes and macrophages are critical effectors and regulators of inflammation and innate immune response, which appear altered in different autoimmune diseases such as systemic lupus erythematosus (SLE). Recent studies suggested that virgin olive oil (VOO) and particularly its phenol compounds might possess preventive effects on different immune-inflammatory diseases, including SLE. Here, we evaluated the effects of VOO (and sunflower oil) on lipopolysaccharide (LPS)-activated peritoneal macrophages from a model of pristane-induced SLE in BALB/c mice, as well as those of the phenol fraction (PF) from VOO on the immune-inflammatory activity and plasticity in monocytes and monocyte-derived macrophages from healthy volunteers. The release of nitrite and inflammatory cytokines was lower in LPS-treated peritoneal macrophages from pristane-SLE mice fed the VOO diet when compared with the sunflower oil diet. PF from VOO similarly decreased the secretion of nitrite and inflammatory cytokines and expression of inducible nitric oxide, PPARγ and Toll-like receptor 4 in LPS-treated human monocytes. PF from VOO also prevented the deregulation of human monocyte subset distribution by LPS and blocked the genetic signature of M1 macrophages while favouring the phenotype of M2 macrophages upon canonical polarisation of naïve human macrophages. For the first time, our study provides several lines of in vivo and in vitro evidence that VOO and PF from VOO target and counteract inflammatory pathways in the monocyte–macrophage lineage of mice with pristane-induced SLE and of healthy subjects, which is a meaningful foundation for further development and application in preclinical and clinical use of PF from VOO in patients with SLE.Artículo Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice(Cambridge University Press, 2015-08-12) Impellizzeri, Daniela; Talero Barrientos, Elena Mª; Siracusa, Rosalba; Alcaide, Antonio; Cordaro, Marika; Zubelia, José María; Motilva Sánchez, Virginia; Universidad de Sevilla. Departamento de FarmacologíaPolyphenols have been described to have a wide range of biological activities, and many reports, published during recent years, have highlighted the beneficial effects of phenolic compounds, illustrating their promising role as therapeutic tools in several acute and chronic disorders. The purpose of study was to evaluate, in an already-assessed model of lung injury caused by bleomycin (BLM) administration, the role of resveratrol and quercetin, as well as to explore the potential beneficial properties of a mango leaf extract, rich in mangiferin, and a grape leaf extract, rich in dihydroquercetin (DHQ), on the same model. Mice were subjected to intra-tracheal administration of BLM, and polyphenols were administered by oral route immediately after BLM instillation and daily for 7 d. Treatment with resveratrol, mangiferin, quercetin and DHQ inhibited oedema formation and body weight loss, as well as ameliorated polymorphonuclear infiltration into the lung tissue and reduced the number of inflammatory cells in bronchoalveolar lavage fluid. Moreover, polyphenols suppressed inducible nitric oxide synthase expression, and prevented oxidative and nitroxidative lung injury, as shown by the reduced nitrotyrosine and poly (ADP-ribose) polymerase levels. The degree of apoptosis, as evaluated by Bid and Bcl-2 balance, was also suppressed after polyphenol treatment. Finally, these natural products down-regulated cyclo-oxygenase-2, extracellular signal-regulated kinase phosphorylated expression and reduced NF-κBp65 translocation. Our findings confirmed the anti-inflammatory effects of resveratrol and quercetin in BLM-induced lung damage, and highlight, for the first time, the protective properties of exogenous administration of mangiferin and DHQ on experimental pulmonary fibrosis.Artículo From pituitary cells to prostate gland in health and disease: direct and indirect endocrine connections(Springer, 2025-02-06) Sarmento-Cabral, André; Fuentes Fayos, Antonio C.; Mata-Ordoñez, Fernando; León González, Antonio José; Martínez Fuentes, Antonio J.; Gahete, Manuel D.; Luque, Raúl M.; Universidad de Sevilla. Departamento de Farmacología; Ministerio de Ciencia, Innovación y Universidades (MICIU). España; Agencia Estatal de Investigación. España; European Union (UE); Junta de AndalucíaThe prostate gland is an endocrine-sensitive organ responding to multiple stimuli. Its development and function are,regulated by multiple hormones (i.e. steroids such as androgens, estrogens and glucocorticoids) but also by other key,hormonal systems such as those comprised by insulin-like growth factor 1 and insulin, which are sourced by different,tissues [e.g. testicles/adrenal-gland/adipose-tissue/liver/pancreas, etc.). Particularly important for the endocrine control,of prostatic pathophysiology and anatomy are hormones produced and/or secreted by different cell types of the pituitary,gland [growth-hormone, luteinizing-hormone, follicle-stimulating hormone, and prolactin, oxytocin, arginine-vasopressin,and melanocyte-stimulating hormone], which affect prostate gland function either directly or indirectly under physiological,and pathophysiological conditions [e.g. metabolic dysregulation (e.g. obesity), and prostate transformations (e.g. prostate,cancer)]. This review summarizes the impact of all pituitary hormone types on prostate gland under these diverse conditions including in vivo and in vitro studies.Artículo BioCart© Opinion-based Study on Home Administration Support for Biological Therapies in Patients with Severe Asthma(Elsevier, 2025-03) Delgado Romero, Julio; Soto Retes, Lorena; Cisneros Serrano, Carolina; Blanco Aparicio, Marina; Ferrando Piqueres, Raúl; Díaz Pérez, David; Merino Bohórquez, Vicente; Universidad de Sevilla. Departamento de FarmacologíaArtículo Impacto del riesgo de múltiples interacciones farmacológicas en el perfil de eventos adversos de pacientes con hepatitis C tratados con antivirales de acción directa pangenotípicos en España(Sociedad Española de Sanidad Penitenciaria, 2024) Turnes, Juan; García Herola, Antonio; Morillo Verdugo, Ramón Alejandro; Méndez, Marinela; Hernández, Cándido; Sicras-Mainar, Antoni; Universidad de Sevilla. Departamento de FarmacologíaObjetivos: Los antivirales de acción directa (AAD) comparten rutas farmacocinéticas con muchas comedicaciones administradas a pacientes con infección crónica por virus de la hepatitis C (VHC). Las guías internacionales recomiendan evaluar el riesgo de interacciones farmacológicas (IF) antes de empezar la terapia con AAD y comedicaciones indicadas. Este estudio evalúa el impacto de las potenciales IF múltiples respecto a los eventos adversos (EA) en pacientes con VHC tratados con AAD en la práctica clínica. Material y método: Es un estudio retrospectivo observacional que utiliza datos de historias clínicas electrónicas. Los pacientes con VHC se trataron con el AAD libre de inhibidores de proteasa sofosbuvir/velpatasvir (SOF/VEL) o glecaprevir/pibrentasvir (GLE/PIB) entre el 2017 y el 2020. Se identificaron potenciales IF (simples y múltiples) utilizando el Liverpool HEP Interaction Checker, y los EA potencialmente asociados a IF durante el tratamiento con AAD. Resultados: Se incluyeron 1.620 pacientes con prescripciones (para SOF/VEL o GLE/PIB). De estos, se predijo que 123 tendrían múltiples IF (población con múltiples IF), que correspondían al 10% (123/1.256) de los que recibieron ≥2 comedicaciones. La mayoría de EA asociados a comedicación se recogieron en la población con múltiples IF (88,9%, 16/18), lo que implica que el 13% (16/123) de la población con múltiples IF sufrió EA. Respecto al régimen de AAD, hubo más EA en los pacientes tratados con GLE/PIB que en los que recibieron SOF/VEL (18,3% [13/71] frente a 5,8% [3/52], p <0,05). Atención primaria informó de más EA que otras especialidades (62,5%). Discusión: Los pacientes con VHC con potenciales IF múltiples tienen alto riesgo de sufrir EA. Se identificaron menos EA asociados a la comedicación con SOF/VEL que con GLE/PIB.Artículo Intervención farmacéutica y percepción del paciente sobre su dolor(Sociedad Española de Farmacia Comunitaria (SEFAC), 2010-09-30) Doukkali, Asmâa; Murillo Fernández, María Dolores; Motilva Sánchez, Virginia; Lacalle Remigio, Juan Ramón; Universidad de Sevilla. Departamento de Medicina Preventiva y Salud Pública; Universidad de Sevilla. Departamento de Farmacología; Universidad de Sevilla. CTS312: Análisis de la Demanda Sanitaria; Universidad de Sevilla. CTS658: Grupo de Investigación en Farmacología Molecular y AplicadaINTRODUCCIÓN: Resulta difícil estimar, medir o valorar el dolor que siente una persona. Sin embargo, su cuantificación es muy importante y su evaluación es una actividad clave derivada de una intervención informativa y educativa para ayudar a mejorar la percepción del paciente sobre su dolor. El objetivo del estudio fue analizar la capacidad de la intervención farmacéutica para valorar el conocimiento del paciente sobre su enfermedad, su medicación y su tratamiento y la mejoría de su percepción dolorosa. MÉTODOS: Estudio observacional, descriptivo y transversal realizado en una farmacia comunitaria de Sevilla. Se llevó a cabo durante un periodo de ocho meses para una muestra de población de treinta pacientes y mediante un seguimiento de dos meses para cada uno. Se midió la percepción del paciente sobre su dolor a través del cuestionario de McGill, se valoró su conocimiento sobre su enfermedad y tratamiento y también el cumplimiento mediante el test de Morisky-Green y unas tablas mensuales. RESULTADOS/DISCUSIÓN: Veintisiete pacientes terminaron el estudio y, según los índices promedios de las cuatro categorías que forman el cuestionario, manifestaron una mejoría en su percepción sobre el dolor. Una intervención farmacéutica basada en una buena información, verbal o escrita, sobre la patología y los medicamentos implica más al paciente en su tratamiento y le ayuda a aliviar su dolor. Eso refuerza la idea de que el farmacéutico juega un papel clave como impulsor del cumplimiento terapéutico mediante una actitud activa y positiva en la dispensación. El cuestionario de McGill ha mostrado ser un instrumento válido, seguro y fiable para medir y valorar el dolor aplicado en el ámbito de la atención farmacéutica.Artículo Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months(Springer Nature, 2017-06-28) Argüelles Arias, Federico; Guerra Veloz, María Fernanda; Perea Amarillo, Raúl; Vilches Arenas, Ángel; Castro Laria, Luisa; Maldonado Pérez, Belén; Chaaro, D.; Merino Bohórquez, Vicente; Romero Gómez, Manuel; Universidad de Sevilla. Departamento de Medicina; Universidad de Sevilla. Departamento de Medicina Preventiva y Salud Pública; Universidad de Sevilla. Departamento de Farmacología; Instituto de Biomedicina de Sevilla (IBIS); Universidad de Sevilla. CTS312: Análisis de la Demanda SanitariaCopyright modification of the article: "Effectiveness and safety of CT-P13 (infliximab biosimilar) in patients with inflammatory bowel disease in real-life settings at 6 months".Artículo Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months(Springer Nature, 2017-06-28) Argüelles Arias, Federico; Guerra Veloz, María Fernanda; Perea Amarillo, Raúl; Vilches Arenas, Ángel; Castro Laria, Luisa; Maldonado Pérez, Belén; Chaaro, D.; Merino Bohórquez, Vicente; Romero Gómez, Manuel; Universidad de Sevilla. Departamento de Medicina; Universidad de Sevilla. Departamento de Medicina Preventiva y Salud Pública; Universidad de Sevilla. Departamento de Farmacología; Instituto de Biomedicina de Sevilla (IBIS); Kern Pharma; Universidad de Sevilla. CTS312: Análisis de la Demanda SanitariaBackground: CT-P13 is a biosimilar of Remicade©, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. Aims: To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice. Methods: This is a prospective observational study in patients with moderate to severe Crohn’s disease or ulcerative colitis treated with CT-P13. The study was performed in one single center. Patients included were naive or switched to anti-TNF treatment from the reference infliximab (Remicade©) to CT-P13. Efficacy and safety were assessed in naive and switched patients who were in remission at the time of the switch at months 3 and 6 of therapy. Results: 87.5 and 83.9% of switched CD patients who were in remission at the time of the switch continued in remission, and 66.7 and 50% of naive CD patients reached remission, at months 3 and 6. In UC switched cases, 92 and 91.3% of patients in remission at the time of the switch continued in remission, at 3 and 6 months. In naive UC patients, the remission rates were 44.4 and 66.7%, at months 3 and 6. Adverse events occurred in 7.5% of patients during 6 months of study. Conclusions: CT-P13 was efficacious and well tolerated in patients with CD or UC.Artículo Advanced sporadic renal epithelioid angiomyolipoma: Case report of an extraordinary response to sirolimus linked to TSC2 mutation(Springer Nature, 2018-05-15) Espinosa, Marta; Roldán-Romero, Juan María; Durán, Ignacio; Álava Casado, Enrique de; Apellaniz-Ruiz, María; Cascón, Alberto; Garrigós, Carmen; Robledo, Mercedes; Rodríguez-Antona, Cristina; Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica; Universidad de Sevilla. Departamento de Farmacología; Ministerio de Economia, Industria y Competitividad (MINECO). EspañaBackground: Renal epithelioid angiomyolipomas (EAML) are rare tumors with aggressive behavior. EAML can be sporadic or develop within the tuberous sclerosis complex syndrome, where mutations of TSC1 or TSC2 genes (critical negative regulators of mTOR Complex 1) result in an increased activation of mTOR pathway. Optimal EAML treatment, including mTOR inhibitors, remains undetermined. Case presentation: Here we present the case of a young adult with a renal EAML that after radical nephrectomy developed metastases, first in liver and then in lumbar vertebrae. After complete surgical resection of these lesions, liver recurrence was detected, this time with incomplete surgical resection. After finding a new liver lesion, systemic treatment with sirolimus started. The patient exhibited a complete and durable response to this drug, being disease free at the time of publication, after 36 months of treatment. Targeted next generation sequencing (NGS) of MTOR, TSC1 and TSC2 genes in the primary tumor, metastasis and blood of the patient, revealed one inactivating TSC2 mutation (c.2739dup; p.K914*) in the tumor cells. Immunohistochemistry revealed decreased TSC2 protein content and increased phospho-S6 in the tumor cells, demonstrating mTOR pathway activation. Conclusion: NGS on an EAML patient with an extraordinary response to sirolimus uncovered TSC2 inactivation as the mechanism for the response. This study supports NGS as a useful tool to identify patients sensitive to mTOR inhibitors and supports the treatment of malignant EAML with these drugs.Artículo Influence of Pharmacist Intervention, Based on CMO Model, to Improve Activation in HIV Patients(Sociedad Española de Quimioterapia, 2019) Morillo Verdugo, Ramón Alejandro; Robustillo Cortés, María de las Aguas; Manzano García, Mercedes; Almeida González, Carmen V.; Universidad de Sevilla. Departamento de FarmacologíaObjectives. The aim of study was to evaluate the influence of pharmacist intervention based on “CMO model”, to improve activation in HIV-patients. Material and methods. Longitudinal, prospective, single- center study. Eligible patients were HIV-infected, taking antiretroviral treatment. The collected data included demographic characteristics, clinical and HIV-related and pharmacotherapeutic variables. The primary outcome was the variation of patient activation measured by Spanish adapted patient activation measure questionnaire. This questionnaire assesses people’s knowledge, skills and confidence in managing their own health care. The assessment was performed at the beginning and 6 months after the program start, which consisted of individualized interventions planned in the stratification model, a motivational interview and a specific pharmacotherapeutic follow-up. Results. A total of 140 patients were included. The most common regimens prescribed were based on non-nucleoside plus nucleoside reverse transcriptase inhibitor (44.0%) and more than half of the patients had chronic concomitant medication. The patients who achieved the highest activation level increased from 28.1% to 68.3% (p<0.0005). The relationship between this increase in patient activation and the stratification level that occurs in largest increases in patients with a low need level, where it was observed an improvement in the percentage of patients with high activation from 28.3% to 74.3% (p<0.001) after intervention. The percentage of patients with adequate adherence to concomitant treatment increased by 18.4% (p = 0.035). Baseline PAM values showed high activation for 28.6% (40 patients), intermediate for 43.6% (61) and low for 27.9% (39). Conclusion. CMO model has an important role for patient activation, improving adherence and health outcomes for HIV+ patients.Artículo Concordance between Pharmacotherapeutic Complexity Calculated and Perceived by HIV+ Patients with Antiretroviral Treatment(Elsevier, 2019) Manzano García, Mercedes; Serrano Giménez, Reyes; Robustillo Cortés, María de las Aguas; Morillo Verdugo, Ramón Alejandro; Universidad de Sevilla. Departamento de FarmacologíaObjective: To determine the difference between the pharmacotherapeutic complexity index by Medication Regimen Complexity Index and it's perceived by patients through a visual analogue scale in patients HIV+ with antiretroviral treatment. Method: Prospective, observational study of patients HIV+ > 18 years of age with stable antiretroviral treatment in the last three months, followed up by external consultations of pharmaceutical care between October’17 and February’18. The main variable of the study was the concordance between the median of the score obtained in the pharmacotherapeutic complexity perceived by the patients using the visual analog scale whose range of values oscillates between 0–10, categorized in low complexity (0–1) and high complexity (2–10), and the median of the score obtained for the theoretical pharmacotherapeutic complexity using the Medication Regimen Complexity Index tool whose ranges of values oscillate between 1 and infinity, categorized in low complexity (0–11) and high complexity > 11. The overall complexity was calculated: antiretroviral treatment and concomitant treatment. Results: We included 236 patients in the study. There was a discrete concordance between the pharmacotherapeutic complexity perceived by the patients and that calculated according to the Medication Regimen Complexity Index tool (Cohen's Kappa index 0.203). The median of the Medication Regimen Complexity Index of the total medication was 6 (interquartile range: 4–10) versus the median of the Complexity Index measured by visual analog scale of 2 (interquartile range: 0–4). Conclusions: Patients perceive a pharmacotherapeutic complexity lower than that calculated. Therefore, we must include the two scales in pharmaceutical care for a better understanding of the patient's perception.